JOURNAL ARTICLE
RESEARCH SUPPORT, NON-U.S. GOV'T
Add like
Add dislike
Add to saved papers

Long-term success of argon laser peripheral iridoplasty in the management of plateau iris syndrome.

Ophthalmology 2004 January
OBJECTIVE: To document the long-term effect of argon laser peripheral iridoplasty (ALPI) in eyes with plateau iris syndrome.

DESIGN: Retrospective, noncomparative, interventional case series.

SETTING: New York Eye and Ear Infirmary.

METHODS: The charts of all patients with plateau iris syndrome treated with ALPI from 1982 to 1991 and subsequently followed for 6 or more years were retrospectively reviewed. Patients with lens-related mechanisms contributing to angle closure (e.g., phacomorphic or malignant glaucoma) were excluded.

MAIN OUTCOME MEASURES: Necessity for repeat ALPI and/or any additional means of intervention.

RESULTS: A total of 26 ALPI procedures were performed in 23 eyes of 14 patients (4 men, 10 women). The mean age was 61+/-8.7 years. The mean follow-up was 78.9+/-8.0 months (range, 72-188 months). The angle in 20 of 23 (87.0%) eyes remained open throughout the entire follow-up period after only 1 treatment with ALPI. In 3 eyes, there was gradual reclosure of the angle 5 to 9 years after initial ALPI, but they were readily reopened and maintained open by a single repeat treatment. No filtration surgery was necessary in any eye during follow-up.

CONCLUSIONS: ALPI is highly effective in eliminating residual appositional closure after laser iridotomy caused by plateau iris syndrome. The effect is maintained for years, although a small proportion of patients might require retreatment.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app